Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

Joseph S. Solomkin, John E. Mazuski, Ellen J. Baron, Robert G. Sawyer, Avery B. Nathens, Joseph T. DiPiro, Timothy Buchman, E. Patchen Dellinger, John Jernigan, Sherwood Gorbach, Anthony W. Chow, and John Bartlett Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri; Department of Microbiology, Stanford University School of Medicine, Palo Alto, California; Department of Surgery, University of Virginia, Charlottesville; Department of Surgery, University of Washington, Seattle; University of Georgia College of Pharmacy, Department of Surgery, Medical College of Georgia, Augusta, and Centers for Disease Control and Prevention, Atlanta; Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

[1]  J. Griffith,et al.  Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  N. Christou,et al.  Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections: Results of a Double-Blind, Randomized Comparative Phase III Trial , 2003, Annals of surgery.

[3]  S. Jenkins,et al.  Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria ; Approved Standard — Seventh Edition , 2003 .

[4]  K. Aldridge,et al.  In Vitro Susceptibilities of the Bacteroides fragilis Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data , 2002, Journal of Clinical Microbiology.

[5]  A. Nathens,et al.  The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. , 2002, Surgical infections.

[6]  A. Bisno,et al.  Diagnosis of strep throat in adults: are clinical criteria really good enough? , 2002, Clinical Infectious Diseases.

[7]  D. Snydman,et al.  National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Coast,et al.  Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness , 2002, Journal of health services research & policy.

[9]  A. Nathens,et al.  The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. , 2002, Surgical infections.

[10]  M A Kish,et al.  Guide to development of practice guidelines. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Wilson,et al.  Results of a Clinical Trial of Clinafloxacin Versus Imipenem/Cilastatin for Intraabdominal Infections , 2001, Annals of surgery.

[12]  V. Dev,et al.  Complicated Appendicitis: Is There a Minimum Intravenous Antibiotic Requirement? A Prospective Randomized Trial , 2000, The American surgeon.

[13]  P. Lipsett,et al.  Comparison of Intravenous/Oral Ciprofloxacin Plus Metronidazole Versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections , 2000, Annals of surgery.

[14]  D. Snydman,et al.  Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  D. Snydman,et al.  Multicenter Study of In Vitro Susceptibility of theBacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996 , 1999, Antimicrobial Agents and Chemotherapy.

[16]  H. Forssell,et al.  Piperacillin/tazobactam compared with cefuroxime/ metronidazole in the treatment of intra-abdominal infections. , 1999, The European journal of surgery = Acta chirurgica.

[17]  H. Levy,et al.  Prophylactic Antibiotics for Severe Acute Pancreatitis: The Beginning of an Era , 1999, Pharmacotherapy.

[18]  M. Silen,et al.  The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. , 1999, Journal of pediatric surgery.

[19]  R. Bennion,et al.  Ticarcillin/Clavulanate versus Imipenem/Cilistatin for the Treatment of Infections Associated with Gangrenous and Perforated Appendicitis , 1999, The American surgeon.

[20]  C. Ohmann,et al.  Risk factors associated with intraabdominal infections: a prospective multicenter study , 1999, Langenbeck's Archives of Surgery.

[21]  J. Brogard,et al.  Biliary tract infections: a guide to drug treatment. , 1999, Drugs.

[22]  C. Ohmann,et al.  Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. , 1999, Langenbeck's archives of surgery.

[23]  D. Luke,et al.  Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. , 1998, American journal of surgery.

[24]  R. Chioléro,et al.  Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis , 1998, Antimicrobial Agents and Chemotherapy.

[25]  C. Burnweit,et al.  Is abdominal cavity culture of any value in appendicitis? , 1998, American journal of surgery.

[26]  B. Rau,et al.  Role of ultrasonographically guided fine‐needle aspiration cytology in the diagnosis of infected pancreatic necrosis , 1998, The British journal of surgery.

[27]  P. Barie,et al.  A Randomized, Double-blind Clinical Trial Comparing Cefepime Plus Metronidazole With Imipenem-Cilastatin in the Treatment of Complicated Intra-abdominal Infections , 1997 .

[28]  D. Gerding,et al.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. , 1997, Infection control and hospital epidemiology.

[29]  E. Taylor,et al.  A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. , 1997, The Journal of antimicrobial chemotherapy.

[30]  A. Basoli,et al.  Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. , 1997, Scandinavian journal of infectious diseases.

[31]  P. Barie,et al.  A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study Group. , 1997, Archives of surgery.

[32]  D. Snydman,et al.  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Bohnen,et al.  Management of Intra-abdominal Infections: The Case for Intraoperative Cultures and Comprehensive Broad-spectrum Antibiotic Coverage , 1996 .

[34]  P. Montravers,et al.  Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  K. Faulkner,et al.  Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. , 1996, The Journal of antimicrobial chemotherapy.

[36]  T. Berne,et al.  Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. , 1996, Journal of the American College of Surgeons.

[37]  J. Bohnen,et al.  Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. , 1996, Annals of surgery.

[38]  D. Gerding,et al.  Does antibiotic restriction prevent resistance? , 1996, New horizons.

[39]  A. Viste,et al.  A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. , 1996, Scandinavian journal of infectious diseases.

[40]  S. Wilson,et al.  Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  S. Geroulanos.  Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. , 1995, The Journal of antimicrobial chemotherapy.

[42]  D. Pezet,et al.  Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. , 1995, The Journal of antimicrobial chemotherapy.

[43]  P. Schauer,et al.  Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. , 1995, The American surgeon.

[44]  B. Bäckstrand,et al.  Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. , 1995, The Journal of antimicrobial chemotherapy.

[45]  P. Barie,et al.  Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. , 1993, The American surgeon.

[46]  C. Ohmann,et al.  Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. , 1993, The European journal of surgery = Acta chirurgica.

[47]  Jeffrey W. Smith,et al.  Efficacy of a β-Lactamase Inhibitor Combination for Serious Intra-abdominal Infections , 1993 .

[48]  P. Barie,et al.  Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. , 1993, Archives of surgery.

[49]  Nord Ce,et al.  A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. , 1993 .

[50]  R. Wilson,et al.  Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. , 1993, Annals of surgery.

[51]  C. Nord,et al.  A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. , 1993, The Journal of antimicrobial chemotherapy.

[52]  B. Bäckstrand,et al.  Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections , 1992, Antimicrobial Agents and Chemotherapy.

[53]  J. Bartlett,et al.  Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  A. Awada,et al.  Streptococcal and enterococcal bacteremia in patients with cancer. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  D. Snydman,et al.  Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis , 1992, Antimicrobial Agents and Chemotherapy.

[56]  J. Bohnen,et al.  Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. , 1992, Archives of surgery.

[57]  D. Dunn,et al.  Antibiotic treatment for surgical peritonitis. , 1991, Annals of surgery.

[58]  L. Navér,et al.  Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. , 1991, The European journal of surgery = Acta chirurgica.

[59]  K. Sirinek,et al.  A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. , 1991, Surgery, gynecology & obstetrics.

[60]  J. Solomkin,et al.  Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. , 1990, Annals of surgery.

[61]  N. Christou,et al.  Imipenem versus tobramycin--antianaerobe antibiotic therapy in intra-abdominal infections. , 1990, Canadian journal of surgery. Journal canadien de chirurgie.

[62]  M. Bergeron,et al.  Pathogenic factors in aminoglycoside-induced nephrotoxicity. , 1990, Toxicology letters.

[63]  P. Francioli,et al.  CLINICAL SIGNIFICANCE OF CANDIDA ISOLATED FROM PERITONEUM IN SURGICAL PATIENTS , 1989, The Lancet.

[64]  S. Wilson,et al.  Cephalosporin therapy in intraabdominal infections. A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin. , 1988, American journal of surgery.

[65]  N. Jacobus,et al.  Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation , 1988, Antimicrobial Agents and Chemotherapy.

[66]  D. Snydman,et al.  Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. , 1987, Diagnostic microbiology and infectious disease.

[67]  Peoples Jb.  Candida and perforated peptic ulcers. , 1986 .

[68]  J. Peoples.  Candida and perforated peptic ulcers. , 1986, Surgery.

[69]  T. Berne,et al.  The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. , 1985, Surgery, gynecology & obstetrics.

[70]  J. Meakins,et al.  Surgical infection stratification system for intra-abdominal infection. Multicenter trial. , 1985, Archives of surgery.

[71]  Fong Iw.  Septic complications of perforated peptic ulcer. , 1983 .

[72]  I. Fong.  Septic complications of perforated peptic ulcer. , 1983, Canadian journal of surgery. Journal canadien de chirurgie.

[73]  T. Berne,et al.  Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. , 1982, American journal of surgery.

[74]  J. Boey,et al.  Bacteria and septic complications in patients with perforated duodenal ulcers. , 1982, American journal of surgery.

[75]  D. Kasper,et al.  Cellular immunity to Bacteroides fragilis capsular polysaccharide , 1982, The Journal of experimental medicine.

[76]  E. Dellinger,et al.  Implications of Leukocytosis and Fever at Conclusion of Antibiotic Therapy for Intra‐abdominal Sepsis , 1982, Annals of surgery.

[77]  R. L. Simmons,et al.  The role of Candida in intraperitoneal infections. , 1980, Surgery.

[78]  E. Dellinger,et al.  Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. , 1980, Archives of surgery.